The Journal of Urology
Volume 179, Issue 4 , Pages 1243-1256 , April 2008

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

  • Chris Mullins

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Financial interest and/or other relationship with AUA Research Council.
    • ,
  • M. Scott Lucia

      Affiliations

    • Prostate Diagnostic Laboratory and MPSA Pathology Coordinating Center, Department of Pathology, University of Colorado Denver and Health Sciences Center, Aurora, Colorado
    • Financial interest and/or other relationship with GlaxoSmithKline and Veridex.
    • ,
  • Simon W. Hayward

      Affiliations

    • Departments of Urologic Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Jeannette Y. Lee

      Affiliations

    • Medical Statistics Section, The University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Jonathan M. Levitt

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, Texas
    • Department of Immunology, Baylor College of Medicine, Houston, Texas
    • Baylor College of Medicine, Houston, Texas
    • ,
  • Victor K. Lin

      Affiliations

    • Department of Urology, The University of Texas, Southwest Medical Center, Dallas, Texas
    • ,
  • Brian C.-S. Liu

      Affiliations

    • Molecular Urology Laboratory, Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Arul M. Chinnaiyan

      Affiliations

    • Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts
    • Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
    • Financial interest and/or other relationship with Compendia, Gen-Probe and Rubicon.
    • ,
  • Mark A. Rubin

      Affiliations

    • Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts
    • Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
    • ,
  • Kevin Slawin

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, Texas
    • Financial interest and/or other relationship with Beckman Coulter, Inc.
    • ,
  • Robert A. Star

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Robert H. Getzenberg

      Affiliations

    • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Financial interest and/or other relationship with University of Pittsburgh and Johns Hopkins University.
    • Corresponding Author InformationCorrespondence: James Buchanan Brady Urological Institute, Johns Hopkins Hospital, 600 N. Wolfe St., Marburg 121, Baltimore, Maryland 21287 (telephone: 410-502-3137; FAX: 410-502-9336).
    • ,
  • MPSA Consortium

Received 8 June 2007

References 

  1. Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002;42:1
  2. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12:S122
  3. Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol. 2005;173:1256
  4. Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber M, Jacobsen SJ. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol. 2003;173:2048
  5. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int. 2004;94:738
  6. McConnell JD, Roehrborn CG, Baustista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387
  7. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15:1677
  8. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485
  9. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem. 1998;100:439
  10. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84:976
  11. Di Silverio F, Gentile V, DeMatteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164
  12. Mahapokai W, van den Ingh TS, van Mil F, van Garderen E, Schalken JA, Mol JA, et al. Immune response in hormonally-induced prostatic hyperplasia in the dog. Vet Immunol Immunopathol. 2001;78:297
  13. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A. 2002;99:7598
  14. Ehrlich JR, Qin S, Liu BC. The ‘reverse capture’ autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc. 2006;1:452
  15. Qin S, Qiu W, Ehrlich JR, Ferdinand AS, Richie JP, O’Leary MP, et al. Development of a “reverse capture” autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics. 2006;6:3199
  16. DiCunto F, Calautti E, Hsiao J, Ong L, Topley G, Turco E, et al. Citron rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein Citron. J Biol Chem. 1998;273:29706
  17. Yamashiro S, Totsukawa G, Yamakita Y, Sasaki Y, Madaule P, Ishizaki T, et al. Citron kinase, a Rho-dependent kinase, induces di-phosphorylation of regulatory light chain of myosin II. Mol Biol Cell. 2003;14:1745
  18. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogential development: a practical approach. Differentiation. 2003;71:402
  19. Shah US, Arlotti J, Dhir R, Lu S, Pirozzi G, Prakash K, et al. Androgen regulation of JM-27 is associated with the diseased prostate. J Androl. 2004;25:618
  20. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol. 2005;174:375
  21. Cannon GW, Mullins C, Lucia MS, Hayward SW, Lin V, Liu BC, et al. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol. 2007;177:610
  22. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987;214:317
  23. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222
  24. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000;55:41
  25. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology. 2002;59:797
  26. Slawin KM, Shariat S, Canto E. BPSA: a novel serum marker for benign prostatic hyperplasia. Rev Urol. 2005;7(suppl):S52
  27. Levitt JM, Slawin KM. Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Prostate Rep. 2007;5:21
  28. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem. 2003;49:253
  29. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004;63:905
  30. Shariat SF, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol. 2004;6:58
  31. Morote J, Encabo G, Lopez M, deTorres IM. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?. Eur Urol. 2000;38:91
  32. Debruyne F, Barkin J, vanErps P, Reis M, Tammela TL, Roehrborn C, et al. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488
  33. Slawin KM, Levitt JM, Lamb DJ, Murthy L, Chuang W, Lu HK, et al. Prediction of prostate volume using molecular forms of PSA in men with BPH enrolled on the GSK Phase III Dutasteride Trials. J Urol. 2006;175(suppl):439;abstract 1363
  34. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549
  35. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care. 1995;33:AS145
  36. Slawin KM, Levitt JM, Lamb DJ, Murthy L, Chuang W, Lu HK, et al. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK Phase III Dutasteride Trials. J Urol. 2006;175(suppl):436;abstract 1352
  37. Slawin KM, Kattan MW, Roehrborn CG, Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology. 2006;67:84
  38. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:109
  39. Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol. 2005;68:149
  40. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469
  41. Falk J, Bonnon C, Girault JA, Faivre-Sarrailh C. F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination. Biol Cell. 2002;94:327
  42. Hu QD, Ang BT, Karsak M, Hu WP, Cui XY, Duka T, et al. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell. 2003;115:163
  43. Hu QD, Ma QH, Gennarini G, Xiao ZC. Cross-talk between F3/contactin and Notch at axoglial interface: a role in oligodendrocyte development. Dev Neurosci. 2006;28:25
  44. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, et al. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol. 1993;24:982
  45. Lynch DF, Hassen W, Clements MA, Schellhammer PF, Wright GL. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate. 1997;32:214
  46. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557
  47. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how?. Eur Urol. 1999;36(suppl):7
  48. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41
  49. Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, et al. Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia. 2006;8:153
  50. Ehrlich JR, Caiazzo RJ, Qiu W, Tassinari OW, O’Leary MP, Richie JP, et al. A native antigen reverse capture microarray platform for autoantibody profiling of prostate cancer sera. Proteomics Clin Appl. 2007;1:476

 Supported by National Institutes of Health Grants DK63593 (RHG), DK63597 (MSL), DK63587 (SWH), DK63661 (VKL), DK63665 (BC-SL), AG022312 (MAR) and DK63594 (KS).

PII: S0022-5347(07)03088-1

doi: 10.1016/j.juro.2007.11.049

The Journal of Urology
Volume 179, Issue 4 , Pages 1243-1256 , April 2008

Article Tools

* Image Usage & Resolution